Program
LAE102
A development code. Also written as “LAE102 intravenous administration”, “LAE102 subcutaneous administration” and “LAE102 multiple subcutaneous administration”.
Its studies are mostly in Overweight · Obesity, led by Laekna.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laekna | 32 open or running | phase 1since Jun 3, 2024 | Jun 3, 2024 | Jun 30, 2027phase 1 · NCT06493084 |
Also a collaborator on its studies: Eli Lilly.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2024First study: phase 1 study in OverweightFirst studyNCT06493084 · 160 enrolled · China
- Mar 27, 2025Phase 1 study in PostmenopausalNCT06908707 · 32 enrolled · United States
- Nov 13, 2025Phase 1 study in OverweightNCT07230496 · 104 planned · Australia
Ahead
- Jun 30, 2027Primary completion: phase 1 study in OverweightNCT06493084
- Mar 20, 2028Primary completion: phase 1 study in OverweightNCT07230496
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230496Overweight · Australia | 1 | Recruiting | Mar 20, 2028 | 104 |
| NCT06908707Postmenopausal · United States | 1 | Completed | Oct 23, 2025 | 32 |
| NCT06493084Overweight · China | 1 | Active, not recruiting | Jun 30, 2027 | 160 |
How it is read
Names in the registry
- “LAE102 intravenous administration”, 1 entry
- “LAE102 subcutaneous administration”, 1 entry
- “LAE102 multiple subcutaneous administration”, 1 entry
- “LAE102 injection in combined with LAE103 injection”, 1 entry
- “LAE102 SC”, 1 entry
Codes read as this program: LAE102.
Conditions, from the studies’ own filings
- Overweight, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.